Epilepsy- Competitive Landscape, Market and Pipeline Analysis, 2018
This report can be delivered to the clients within 48 hours
'Epilepsy- Competitive Landscape, Market and Pipeline Analysis, 2018', report provides comprehensive insights about marketed and pipeline drugs across this indication. The report provides the detailed analysis of 115+ products along with 45+ companies involved. Ultragenyx Pharmaceuticals, Takeda, and Pfizer are among the developers of most promising pipeline products.
Products covered by Phase
Pipeline analysis of 115+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details. Report contains the development and sale activities for marketed drugs.
Therapeutic segmentation of products for Epilepsy
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this Immunotherapy.
METHODOLOGY
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
SCOPE
'Epilepsy- Competitive Landscape, Market and Pipeline Analysis, 2018', report provides comprehensive insights about marketed and pipeline drugs across this indication. The report provides the detailed analysis of 115+ products along with 45+ companies involved. Ultragenyx Pharmaceuticals, Takeda, and Pfizer are among the developers of most promising pipeline products.
Products covered by Phase
- Marketed Products
- Phase III, Phase II and Phase I
- Pre-clinical, Discovery and Unknown Phase
Pipeline analysis of 115+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details. Report contains the development and sale activities for marketed drugs.
Therapeutic segmentation of products for Epilepsy
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this Immunotherapy.
METHODOLOGY
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
SCOPE
- The report provides competitive pipeline landscape of Epilepsy
- The report provides the marketed drugs information including its sales, development activities and details of patent expiry
- The report provides the insight of current and future market for Epilepsy
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Epilepsy pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Epilepsy and also provide company profiling
- Pipeline products coverage based on various stages of development ranging from late stage till discovery stage
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
- Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
- Establish a comprehensive understanding of the current pipeline scenario Epilepsy to formulate effective R&D strategies
- Assess challenges and opportunities that influence Epilepsy R&D
- Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
- Devise corrective measures for pipeline projects by understanding Epilepsy pipeline depth and focus of indication therapeutics
- Developing strategic initiatives to support your drug development activities
- Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Epilepsy to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive drugs
- Gaining a full picture of the Competitive Landscape for Evidence based Decisions
Executive Summary
Overview
Competitive Landscape
Marketed Products
Drug Description
Commercial Activities
Product Profile
Vimpat Sales
(The list Continues)
Pipeline Therapeutics
Late Stage Products
Comparative Analysis
Cannabidiol: INSYS Therapeutics
Product Description
Research and Development
Product Development Activities
(The list continues)
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I)
Comparative Analysis
Therapeutic Assessment: Phase Products
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Pre-clinical, Discovery and Unknown Products
Comparative Analysis
Dormant & Discontinued Products
Comparative Analysis
Market Drivers and Barriers
Appendix
Overview
Competitive Landscape
Marketed Products
Drug Description
Commercial Activities
Product Profile
Vimpat Sales
(The list Continues)
Pipeline Therapeutics
Late Stage Products
Comparative Analysis
Cannabidiol: INSYS Therapeutics
Product Description
Research and Development
Product Development Activities
(The list continues)
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I)
Comparative Analysis
Therapeutic Assessment: Phase Products
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Pre-clinical, Discovery and Unknown Products
Comparative Analysis
Dormant & Discontinued Products
Comparative Analysis
Market Drivers and Barriers
Appendix
LIST OF TABLES
Table 1: Total Products for Epilepsy
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Assessment by Monotherapy Products
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Pre-clinical, Discovery and Unknown Stage Products
Table 11: Dormant & Discontinued Products
Table 1: Total Products for Epilepsy
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Assessment by Monotherapy Products
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Pre-clinical, Discovery and Unknown Stage Products
Table 11: Dormant & Discontinued Products
LIST OF FIGURES
Figure 1: Pathophysiology of Epilepsy
Figure 2: Vimpat-Historical Sales (2012-2017)
Figure 3: Lyrica-Historical Sales (2012-2017)
Figure 4: Keppra-Historical Sales (2012-2017)
Figure 5: Keppra-Historical Sales (2012-2017)
Figure 6: Topamax-Historical Sales (2012-2017)
Figure 7: Lamictal-Historical Sales (2012-2017)
Figure 8: Neurontin-Historical Sales (2012-2017)
Figure 9: Zonegran-Historical Sales (2012-2017)
Figure 10: Trileptal-Historical Sales (2012-2017)
Figure 11: Zebinix-Historical Sales (2012-2017)
Figure 12: Fycompa-Historical Sales (2012-2017)
Figure 13: Total Products for Epilepsy
Figure 14: Late Stage Products (Phase III)
Figure 15: Mid Stage Products (Phase II)
Figure 16: Early Stage Products (Phase I)
Figure 17: Assessment by Monotherapy Products
Figure 18: Assessment by Route of Administration
Figure 19: Assessment by Stage and Route of Administration
Figure 20: Assessment by Molecule Type
Figure 21: Assessment by Stage and Molecule Type
Figure 22: Pre-clinical, Discovery and Unknown Stage Products
Figure 23: Dormant & Discontinued Products
Figure 1: Pathophysiology of Epilepsy
Figure 2: Vimpat-Historical Sales (2012-2017)
Figure 3: Lyrica-Historical Sales (2012-2017)
Figure 4: Keppra-Historical Sales (2012-2017)
Figure 5: Keppra-Historical Sales (2012-2017)
Figure 6: Topamax-Historical Sales (2012-2017)
Figure 7: Lamictal-Historical Sales (2012-2017)
Figure 8: Neurontin-Historical Sales (2012-2017)
Figure 9: Zonegran-Historical Sales (2012-2017)
Figure 10: Trileptal-Historical Sales (2012-2017)
Figure 11: Zebinix-Historical Sales (2012-2017)
Figure 12: Fycompa-Historical Sales (2012-2017)
Figure 13: Total Products for Epilepsy
Figure 14: Late Stage Products (Phase III)
Figure 15: Mid Stage Products (Phase II)
Figure 16: Early Stage Products (Phase I)
Figure 17: Assessment by Monotherapy Products
Figure 18: Assessment by Route of Administration
Figure 19: Assessment by Stage and Route of Administration
Figure 20: Assessment by Molecule Type
Figure 21: Assessment by Stage and Molecule Type
Figure 22: Pre-clinical, Discovery and Unknown Stage Products
Figure 23: Dormant & Discontinued Products
